scholarly journals Chinese Herbal Prescription Fu-Zheng-Qu-Xie Prevents Recurrence and Metastasis of Postoperative Early-Stage Lung Adenocarcinoma: A Prospective Cohort Study Followed with Potential Mechanism Exploration

2021 ◽  
Vol 2021 ◽  
pp. 1-22
Author(s):  
Sufang Zhang ◽  
Wanqing Chen ◽  
Yuli Wang ◽  
Jianchun Wu ◽  
Lili Xu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Lung Adenocarcinoma ◽  
Immune Function ◽  
Cancer Progression ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Early Stage ◽  
Xenograft Model ◽  
Chinese Herbal

Chinese herbal Fu-Zheng-Qu-Xie (FZQX) prescription has been found to improve the immune function and survival of patients with early-stage lung cancer. However, the therapeutic efficacy needs to be evaluated objectively, and the precise mechanism remains unclear. In the present study, a double-center, prospective cohort study was carried out to assess the clinical efficacy of the FZQX prescription in preventing the recurrence and metastasis of postoperative early-stage lung adenocarcinoma. Our results indicated that the FZQX prescription could significantly reduce the 3-year postoperative recurrence rate and improve the life quality. Moreover, the peripheral blood indices showed that the positive immune index (CD4+T/CD8+T) increased and the negative immune indices (CD8+T, Myeloid-derived suppressor cells (MDSCs), Treg) decreased after treatment with the FZQX prescription. Since the positive regulatory effect of the FZQX prescription on immune function, a series of experiments were conducted to verify the tumor-suppressive effect and elucidate the underlying mechanisms. Through the MDSC clearance xenograft model, we confirmed that the FZQX prescription could effectively suppress tumor growth with lesser side effects in vivo, and MDSCs may be involved in the biological process of the FZQX prescription’s intervention in lung cancer progression. By establishing the coculture system of MDSCs/LLC to simulate the immune microenvironment of lung cancer, the tumor suppression effect of the FZQX prescription was further validated by in vitro experiments. Besides, it was confirmed that the FZQX prescription could regulate MDSCs to remodel the immunosuppressive tumor microenvironment, thus exerting its preventive effect on relapse of lung cancer. Finally, the pathway activator and inhibitor were further used to explore the potential molecular mechanism. Results demonstrated that the IL-1β/NF-κB signaling pathway was one of the critical signaling pathways of FZQX prescription regulating MDSCs to prevent the recurrence and metastasis of lung adenocarcinoma.

Camrelizumab in the treatment of patients with advanced lung cancer: A multicenter, prospective, cohort study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21650-e21650
Author(s):  
Rong Wang ◽  
Mei Ji ◽  
Meiqi Shi ◽  
Dong Hua ◽  
Lianke Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Real World ◽  
Prospective Cohort ◽  
Early Stage ◽  
Antitumour Activity ◽  
Objective Response ◽  
Squamous Carcinoma ◽  
Advanced Lung Cancer

e21650 Background: Camrelizumab is a humanized PD-1 monoclonal antibody. The efficacy of camrelizumab monotherapy or combined with chemotherapy in the treatment of advanced NSCLC had been demonstrated with promising anti-tumor activity in previous studies. However, in the real-world clinical practice, the activity of camrelizumab in patients with advanced lung cancer is poorly characterised. We sought to analyse the antitumour activity and toxicity of camrelizumab in advanced lung cancer to explore benefit subgroups and optimal treatments. Methods: This is a multicentre, prospective cohort study of advanced lung cancer in Jiangsu province, China. Eligibility required patients with histologically confirmed advanced lung cancer who couldreceive treatment regimen based on camrelizumab. No other restrictive inclusion criteria were applied. Data were captured with electronic uniform database templates to ensure consistent data collection. Primary endpoint is progression-free survival (PFS), Secondary endpoints are adverse events (AE), objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results: 97 pts with advanced lung cancer were enrolled from August 7, 2019 to December 20, 2019. Median age was 64, male 82.5%, adenocarcinoma 50.5%, squamous carcinoma 29.9%, SCLC 14.4%. 30.9% were treated as first-line therapy, 24.7% were second-line treatment, 44.4% were third-line and above treatment. Treatment regimens included camrelizumab monotherapy 13.4%, combination chemotherapy 52.6%, combination anti-angiogenic therapy 24.7%. 52 pts were accessable for efficacy analysis. 11 (21%), 37(71%), and 6(8%) patients showed partial response (PR), stable disease (SD), and progression disease (PD), respectively. The ORR, DCR was 21.2%, 92.3%. 72 pts had experienced the safety assessment. This was an early stage of data analysis, PFS has not yet reached. Major AE was reactive cutaneous capillary hyperplasia (RCCEP) (20/72), no Grade≥3 RCCEP occurred. Other common AEs were eutrophil count decreased (14/72), nausea (12/72), fatigue (11/72), white blood cell decreased (10/72). No treatment-related deaths occurred. Conclusions: This Real-world research showed current treatment status of advanced lung cancer and provides preliminary evidence for camrelizumab treating with advanced lung cancer, and we expect follow-up data to provide more clues. Clinical trial information: ChiCTR1900026089.

Inequality in sentinel lymph node dissection for elderly women with early stage breast cancer: Results from a French prospective cohort study

2012 ◽  
Vol 3 (3) ◽  
pp. 212-219 ◽  
Author(s):  
Camille Cluze ◽  
Frédérique Retornaz ◽  
Dominique Rey ◽  
Mégane Meresse ◽  
Frédérique Rousseau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Node Dissection ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Elderly Women ◽  
Early Stage ◽  
Node Dissection

scholarly journals Predictors of anxiety in early-stage Parkinson's disease – Results from the first two years of a prospective cohort study

2017 ◽  
Vol 43 ◽  
pp. 49-55 ◽  
Author(s):  
Sonja Rutten ◽  
Peter M. van der Ven ◽  
Daniel Weintraub ◽  
Gregory M. Pontone ◽  
Albert F.G. Leentjens ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Early Stage

scholarly journals Perioperative outcome of lung cancer surgery in women: results from a Spanish nationwide prospective cohort study

2019 ◽  
Vol 11 (4) ◽  
pp. 1475-1484 ◽  
Author(s):  
Juan J. Fibla ◽  
◽  
Laureano Molins ◽  
Florencio Quero ◽  
José Miguel Izquierdo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Lung Cancer Surgery ◽  
Cancer Surgery ◽  
Perioperative Outcome

scholarly journals PCN252 RISK OF LUNG CANCER AMONG SMOKING WOMEN TREATED WITH RADIOTHERAPY FOR PRIMARY BREAST CANCER: FRENCH PROSPECTIVE COHORT STUDY

2019 ◽  
Vol 22 ◽  
pp. S484
Author(s):  
N. Dohollou ◽  
H. Blachère ◽  
S. Galland-Girodet ◽  
D. Labrosse ◽  
K. Loba ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Primary Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document